OBJECTIVES: The purpose of this study was to determine the role of circulating endothelial progenitor cells with osteoblastic phenotype (EPC-OCN) in human aortic valve calcification (AVC). BACKGROUND: Recent evidence suggests that rather than passive mineralization, AVC is an active atherosclerotic process with an osteoblastic component resembling coronary calcification. We have recently identified circulating EPCs with osteogenic properties carrying both endothelial progenitor (CD34, KDR) and osteoblastic (osteocalcin [OCN]) cell surface markers. METHODS: Blood samples from controls (n = 22) and patients with mild to moderate calcific aortic stenosis (mi-moAS, n = 17), severe calcific AS (sAS, n = 26), and both sAS and severe coronary artery disease (sCAD) (n = 33) were collected during diagnostic coronary angiography. By using flow cytometry, peripheral blood mononuclear cells were analyzed for CD34, KDR, and OCN. Resected normal and calcified aortic valves were analyzed histologically. RESULTS: Patients with mi-moAS and patients with sAS/sCAD had significantly less EPCs (CD34+/KDR+/OCN-) than controls. Patients with sAS showed significantly higher numbers of EPC-OCN (CD34+/KDR+/OCN+) than controls. In addition, the percentage of EPC costaining for OCN was higher in all disease groups compared with controls. A subgroup analysis of younger patients with bicuspid sAS showed a similar pattern of significantly lower EPCs but a high percentage of coexpression of OCN. Immunofluorescence showed colocalization of nuclear factor kappa-B and OCN in diseased and normal valves. CD34+/OCN+ cells were abundant in the endothelial and deeper cell layers of calcific aortic valve tissue but not in normal aortic valve tissue. CONCLUSIONS: Circulating EPC-OCN may play a significant role in the pathogenesis and as markers of prognostication of calcific AS.
OBJECTIVES: The purpose of this study was to determine the role of circulating endothelial progenitor cells with osteoblastic phenotype (EPC-OCN) in humanaortic valve calcification (AVC). BACKGROUND: Recent evidence suggests that rather than passive mineralization, AVC is an active atherosclerotic process with an osteoblastic component resembling coronary calcification. We have recently identified circulating EPCs with osteogenic properties carrying both endothelial progenitor (CD34, KDR) and osteoblastic (osteocalcin [OCN]) cell surface markers. METHODS: Blood samples from controls (n = 22) and patients with mild to moderate calcific aortic stenosis (mi-moAS, n = 17), severe calcific AS (sAS, n = 26), and both sAS and severe coronary artery disease (sCAD) (n = 33) were collected during diagnostic coronary angiography. By using flow cytometry, peripheral blood mononuclear cells were analyzed for CD34, KDR, and OCN. Resected normal and calcified aortic valves were analyzed histologically. RESULTS:Patients with mi-moAS and patients with sAS/sCAD had significantly less EPCs (CD34+/KDR+/OCN-) than controls. Patients with sAS showed significantly higher numbers of EPC-OCN (CD34+/KDR+/OCN+) than controls. In addition, the percentage of EPC costaining for OCN was higher in all disease groups compared with controls. A subgroup analysis of younger patients with bicuspid sAS showed a similar pattern of significantly lower EPCs but a high percentage of coexpression of OCN. Immunofluorescence showed colocalization of nuclear factor kappa-B and OCN in diseased and normal valves. CD34+/OCN+ cells were abundant in the endothelial and deeper cell layers of calcific aortic valve tissue but not in normal aortic valve tissue. CONCLUSIONS: Circulating EPC-OCN may play a significant role in the pathogenesis and as markers of prognostication of calcific AS.
Authors: G Paranya; S Vineberg; E Dvorin; S Kaushal; S J Roth; E Rabkin; F J Schoen; J Bischoff Journal: Am J Pathol Date: 2001-10 Impact factor: 4.307
Authors: Jens J Kaden; Svetlana Bickelhaupt; Rainer Grobholz; Karl K Haase; Aslihan Sarikoç; Refika Kiliç; Martina Brueckmann; Siegfried Lang; Ingrid Zahn; Christian Vahl; Siegfried Hagl; Carl Erik Dempfle; Martin Borggrefe Journal: J Mol Cell Cardiol Date: 2004-01 Impact factor: 5.000
Authors: Yu Kataoka; Kathy Wolski; Kiyoko Uno; Rishi Puri; E Murat Tuzcu; Steven E Nissen; Stephen J Nicholls Journal: J Am Coll Cardiol Date: 2012-05-01 Impact factor: 24.094
Authors: C M Otto; I G Burwash; M E Legget; B I Munt; M Fujioka; N L Healy; C D Kraft; C Y Miyake-Hull; R G Schwaegler Journal: Circulation Date: 1997-05-06 Impact factor: 29.690
Authors: Nalini M Rajamannan; Malayannan Subramaniam; David Rickard; Stuart R Stock; Janis Donovan; Margaret Springett; Thomas Orszulak; David A Fullerton; A J Tajik; Robert O Bonow; Thomas Spelsberg Journal: Circulation Date: 2003-04-28 Impact factor: 29.690
Authors: Mohammed Al-Hijji; Nupoor Narula; Jason L Go; Sundeep Khosla; Maurice Enriquez-Sarano; Darrell Loeffler; Ryan Lennon; Lilach O Lerman; Amir Lerman Journal: Mayo Clin Proc Date: 2019-04 Impact factor: 7.616
Authors: Min Wu; Jian-Dong Zhang; Ri-Ning Tang; Steven D Crowley; Hong Liu; Lin-Li Lv; Kun-Ling Ma; Bi-Cheng Liu Journal: Am J Physiol Renal Physiol Date: 2016-08-31